All In MedTech

FDA Clearance Tracker · P160037-S021

Onclarity HPV Assay

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 12, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P160037-S021
Device name
Onclarity HPV Assay
Applicant location
Sparks, MD
Received
Feb 11, 2025
Decided
Mar 12, 2025
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P160037

Device type

Device class
Class III

Every decision under product code MAQ

FDA's approval statement

As written in FDA's record.

Approval of the SHIP-Sub-Protocol LMI-001-A-S01_Version 3.0 for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P160037-S017.

Source documents

Other decisions for Becton, Dickinson and Company

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.